Skip to main content



Chairman and
Chief Executive Officer

Mr. Iwicki has more than 25 years of experience leading all aspects of R&D and commercialization in the biopharmaceutical industry. He is the Chairman, President and CEO of Kala Pharmaceuticals and was previously the CEO of Civitas Therapeutics which was acquired by Acorda Therapeutics. Prior to Civitas, Mr. Iwicki served as the President and Chief Executive Officer of Blend Therapeutics and President and Chief Executive Officer of Sunovion Pharmaceuticals. He was President and Chief Operating Officer at Sepracor, which was acquired in 2009. During his tenure at Novartis he was Business Unit Head and managed the Cardiovascular, Diabetes, Arthritis, Bone, Gastrointestinal, HRT, Infectious Diseases and Urology therapeutic areas. Previously, Mr. Iwicki held management positions at Merck and Astra Merck. He also currently serves on the boards of Aimmune Therapeutics, Inc., Merus N.V., Pulmatrix Inc. and Akero Therapeutics, Inc., all publicly-traded companies, and Nimbus Therapeutics, Inc. and Oxeia Biopharmaceuticals, Inc., which are privately-held biotech companies. Mr. Iwicki holds a B.S. from Ball State University and an M.B.A. from Loyola University.


Chief Operating Officer

Mr. Bazemore is a biopharmaceutical executive with 25 years of experience spanning from ultra-rare orphan diseases to large primary care conditions. Prior to joining Kala Pharmaceuticals, Todd served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (USA), Inc. since September 2016, where he was instrumental in building the U.S. operations to support the company’s regulatory and commercial strategy. Prior to joining Santhera U.S., Todd served as Executive Vice President and Chief Commercial Officer of Dyax Corp., where he was responsible for global commercial strategy and oversight of all commercial functions. Dyax was acquired by Shire Plc in January of 2016. Prior to joining Dyax, Todd was at Sunovion Pharmaceuticals, Inc. (previously Sepracor Inc., prior to its acquisition by Sumitomo Dainippon Pharma Co., Ltd), where he served in several roles of increasing responsibility including Vice President, Managed Markets, Vice President of Sales, and Vice President of Respiratory Business Unit. He began his career in sales at MURO Pharmaceuticals. Todd has a Bachelor’s of Science in Health from the University of Massachusetts at Lowell.


Chief Medical Officer

Dr. Brazzell has served as our Chief Medical Officer since February 2013. He has also served as a Principal of Acuity Advisors, LLC, an ophthalmic consulting company, from January 2014 to July 2018. Dr. Brazzell served as Chief Medical Officer of Mimetogen Pharmaceuticals, Inc., a clinical stage biotechnology company, from January 2012 until December 2015. Dr. Brazzell also held several executive positions at Inspire Pharmaceuticals, Inc., or Inspire, a specialty pharmaceutical company focusing on ophthalmic products, including Executive Vice President of Medical and Scientific Affairs from 2010 to 2011, Executive Vice President and Head of Ophthalmology Business from 2009 to 2010, and Senior Vice President of Ophthalmic Research and Development from 2004 to 2008. Prior to joining Inspire, Dr. Brazzell served as Global Head of Clinical R&D and Senior Vice President, U.S. R&D, of Novartis Ophthalmics AG from 2000 to 2004. Dr. Brazzell also served as Vice President, R&D at Ciba Vision Ophthalmics, Inc. and as Associate Director, R&D, at Alcon Laboratories, Inc. Dr. Brazzell received a B.S. in Pharmacy and a PhD in Pharmaceutical Sciences from the University of Kentucky.


Chief Scientific Officer

Dr. Chen has served as our Chief Scientific Officer since October 2014. Prior to that, Dr. Chen served as our Executive Vice President of Research from October 2013 to October 2014 and our Vice President of Research from January 2010 to October 2013. Prior to joining us, Dr. Chen served as Director of Formulation Development at TransForm Pharmaceuticals Inc., or TransForm, from 2000 to January 2010. Before joining TransForm, Dr. Chen conducted vaccine delivery research and development at AstraZeneca plc from 1997 to 2000, and at Merck & Co., Inc. from 1996 to 1997. Dr. Chen is a member of the National Academy of Engineering, the College of Fellows of the American Institute for Medical and Biological Engineering and the College of Fellows of the Controlled Release Society. Dr. Chen received a B.S. in Chemical Engineering from The University of Texas at Austin in 1992 and both an M.S. and a ScD. in Chemical Engineering from the Massachusetts Institute of Technology.


Chief Financial Officer

Ms. Reumuth has served as our Chief Financial Officer since July 2017, Senior Vice President, Finance from February 2017 to July 2017, our Vice President, Finance from December 2014 to February 2017, our Senior Director, Finance from February 2014 to December 2014, as our Corporate Controller from February 2014 to July 2017 and Treasurer since February 2014. Prior to joining us, Ms. Reumuth acted as an independent financial consultant from November 2012 to January 2014 and, prior to that, served as Corporate Controller for Enobia Pharma Corp., or Enobia, a global biopharmaceutical company acquired by Alexion Pharmaceuticals, Inc., from May 2011 to June 2012. Prior to Enobia, Ms. Reumuth served as Director of Finance at Verenium Corporation, or Verenium, a biotechnology company, from December 2007 to March 2011. From 2001 to 2007, Ms. Reumuth held a variety of finance and accounting positions at Genzyme Corporation, or Genzyme, (now a Sanofi Company), and ILEX Oncology, Inc., or ILEX (acquired by Genzyme). Prior to ILEX, Ms. Reumuth was an auditor at Ernst & Young LLP. Ms. Reumuth earned her Bachelor’s degree in Business Administration from Texas A&M University—Corpus Christi, and is a Certified Public Accountant.


General Counsel and Chief Compliance Officer

Mr. Trachtenberg has been practicing law for over 20 years, most of which has been spent in the life sciences industry. He has served as our General Counsel and Corporate Secretary since April 2018 and as our Chief Compliance Officer since June 2018. Previously, he served as General Counsel, Chief Compliance Officer and Corporate Secretary of Aralez Pharmaceuticals Inc., from February 2016 to March 2018. Prior to that, he served in similar capacities for Pozen Inc., Aralez’s predecessor, from June 2015 to February 2016. Mr. Trachtenberg also formerly served as Deputy General Counsel at Auxilium Pharmaceuticals, Inc. from May 2012 through its acquisition by Endo Pharmaceuticals in February 2015. Prior to Auxilium, he was Vice President, General Counsel and Corporate Secretary of Enobia Pharma, Inc. from April 2011 through its acquisition by Alexion Pharmaceuticals in April 2012. Prior to that, Mr. Trachtenberg served as Vice President and Associate General Counsel of Sepracor Inc. (now known as Sunovion Pharmaceuticals Inc.) commencing in May 2007 and remained in that position following the acquisition of Sepracor Inc. by Dainippon Sumitomo Pharma through April 2011. Mr. Trachtenberg also held a Senior Counsel position at Kos Pharmaceuticals, Inc. from July 2005 to April 2007 before its acquisition by Abbott. Mr. Trachtenberg began his career at Blank Rome LLP. He holds a Juris Doctorate and Master of Business Administration from Temple University and a Bachelor of Science in Management from Tulane University.

Susan Coultas, PhD

Senior Vice President of Clinical Development

As Senior Vice President of Clinical Development, Dr. Susan Coultas provides Kala Pharmaceuticals, Inc. with 35 years of experience in clinical development in the pharmaceutical and biotechnology industry in both employee and consultant positions. Dr. Coultas has experience working with many ophthalmic companies including Alcon Laboratories, Inc., CibaVision Ophthalmics, Sucampo Pharmaceuticals, and Bausch+Lomb, Inc. As owner of InfoQuest Clinical Network, Inc., (IQCNI) Dr. Coultas successfully identified, developed, and led a large network of clinical research professionals. Projects managed by IQCNI included numerous clinical trials in multiple systemic and ophthalmic therapeutic areas driven to successful, on-time or early completion of projects with exemplary results with regard to quality of data submitted in support of the regulatory path identified. In her current role at Kala, Dr. Coultas has been a key leader in guiding clinical programs that resulted in two NDAs filed and two product commercialized. Dr. Coultas holds a PhD in Public Health, Epidemiology and an M.S. and B.S. in Biology.

Kate Kline

Senior Vice President, Marketing

Ms. Kline has more than 20 years experience in pharmaceutical and medical device sales, marketing and managed markets. She joined Kala Pharmaceuticals in 2018 to build the company’s ophthalmology commercial structure and successfully launched INVELTYS in 2019. Prior to Kala, she held roles of increasing responsibility at Bausch and Lomb/Valeant Pharmaceuticals, including Vice President, Marketing, Ophthalmology and Women’s Health during which she led the strategic direction of ophthalmology franchise and had marketing responsibility for the anti-inflammatory franchise. She previously held managed markets and marketing roles at Allergan Pharmaceuticals, where she helped build the dry eye franchise and disease state that launched RESTASIS®. Ms. Kline holds a Bachelor of Arts in Marketing & Communications from Temple University.


Senior Vice President of Manufacturing
and Supply Chain Management

Mr. Kosewski has served as our Senior Vice President of Manufacturing and Supply Chain Management since July 2017. Prior to joining us, Mr. Kosewski served as Vice President, Supply Chain Operations at Sunovion Pharmaceuticals Inc. from October 2010 to June 2017. He was also Vice President and General Manager at Sunovion’s manufacturing subsidiary, Sepracor Canada Ltd., from 2010 to 2015. Prior to joining Sunovion, Mr. Kosewski held several positions at Sepracor, Inc., including Vice President, Supply Chain Operations from 2007 to 2010. Mr. Kosewski began his pharmaceutical career at Astra USA, Inc., holding positions in quality assurance, manufacturing, procurement and business development. Mr. Kosewski holds a B.S. in Chemistry from Fairfield University and an M.B.A.from Bryant University.

Steven Zhang, MD, PhD

Senior Vice President of Medical Affairs

Dr. Zhang has over 15 years of experience in pharmaceutical medical affairs with more than 10 years in the ophthalmic industry. Dr. Zhang joined Kala in August 2018 as Vice President of Medical Affairs. Prior to joining Kala, Dr. Zhang was the Head of US Ophthalmic Medical Affairs and Global Ophthalmic Franchise Medical Lead at Shire Plc. Dr. Zhang began his industry career at Abbott Laboratories Inc., holding positions in clinical and medical sciences at Abbott and Bausch+Lomb Inc. Dr. Zhang has a MD degree, a Master’s degree in pharmacology and a PhD degree in biophysics with training and research at the California Institute of Technology (Caltech).


Chief Business Officer

Mr. Kharabi has served as our Chief Business Officer since November 2021. Mr. Kharabi formerly served as President and Chief Executive Officer of Combangio, and is the co-founder of Lagunita Biosciences LLC, a biotechnology and medical investment company and incubator. He previously served in executive management for xCella and Kedalion, two Lagunita portfolio companies, helping to build early value, raise financing and recruit full-time leadership teams. Prior to Lagunita, he served as Vice President, Corporate Development and International Sales at OrthAlign Inc., a commercial stage orthopedic surgery navigation company, where his responsibilities included the launch of the KneeAlign® total knee arthroplasty navigation product line in North America, Europe, Asia and Australia. Mr. Kharabi started his career as a biotechnology licensing attorney at Wilson, Sonsini Goodrich & Rosati PC. He received his B.S. in Biochemistry from Georgetown University and his J.D. and M.B.A. degrees from Stanford University.

Please review our Privacy Statement(opens new window). This website uses cookies. By using our website without changing your cookie settings you agree to our use of cookies as described in our Privacy Statement(opens new window).